Haemonetics Acquires Vivasure Medical for €100 Million to Enhance Vascular Access Solutions
Written by Emily J. Thompson, Senior Investment Analyst
Source: Benzinga
- Acquisition Strategy: Haemonetics is acquiring Ireland-based Vivasure Medical for €100 million (approximately $117 million) to strengthen its position in structural heart and endovascular procedures, addressing the rising demand for large-bore vascular access.
- Technology Integration: The deal adds Vivasure's PerQseal Elite system to Haemonetics' interventional portfolio, designed to close large-bore arterial and venous access sites using a proprietary bioabsorbable patch, which aims to streamline workflows and reduce complication risks during complex cardiovascular interventions.
- Funding Source: Haemonetics will fund the acquisition with $296.4 million in cash on hand as of September 27, 2025, demonstrating the company's commitment to scaling differentiated technologies in rapidly growing procedural categories.
- Future Outlook: The company plans to publish its third-quarter fiscal 2026 results on February 5, which may provide additional insights into capital deployment and integration priorities, further enhancing investor confidence in its growth trajectory.
Analyst Views on HAE
Wall Street analysts forecast HAE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HAE is 88.86 USD with a low forecast of 74.00 USD and a high forecast of 99.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
4 Buy
4 Hold
0 Sell
Moderate Buy
Current: 68.370
Low
74.00
Averages
88.86
High
99.00
Current: 68.370
Low
74.00
Averages
88.86
High
99.00
About HAE
Haemonetics Corporation is a medical technology company. Its solutions address critical medical needs, which includes a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers, and products to enable blood centers to collect in-demand blood components. Its Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. Its Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies (Hemostasis Management, Cell Salvage and Transfusion Management products). It also offers solutions for structural heart and endovascular procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
